Ongoing Clinical Trials for Pneumonia Chlamydial
Currently, there are 2 ongoing clinical trials investigating new treatment approaches for community-acquired pneumonia. These studies are being conducted in France and Denmark, focusing on optimizing antibiotic treatment duration and testing alternative delivery methods for antibiotics.
Clinical trial locations
- Denmark
- France
Study on Customized Antibiotic Treatment Duration for Hospitalized Patients with Community-Acquired Pneumonia Using Cefotaxime and Drug Combination
This trial is taking place in France and explores a new approach to determining how long patients should take antibiotics for community-acquired pneumonia. Instead of following a standard fixed duration, the study tests whether stopping antibiotics when certain health markers show stability is just as effective.
Who can participate: The study is looking for adults aged 18 years or older who have been hospitalized with suspected community-acquired pneumonia. To join, participants must have symptoms such as fever, shortness of breath, cough, or crackling sounds in the lungs, along with visible lung changes on a chest X-ray or CT scan. Patients must have already been treated with antibiotics for at least 48 hours but no more than 7 days, and they need to show signs of clinical improvement in the last 24 hours. This includes having a normal body temperature, heart rate under 100 beats per minute, breathing rate under 24 breaths per minute, and adequate oxygen levels. Participants must also have a negative viral respiratory test or proof of bacterial infection if the viral test is positive.
Who cannot participate: The trial excludes patients under 18 or over 65 years old, pregnant or breastfeeding women, and those with a weakened immune system. People currently participating in another clinical trial, those with severe allergic reactions to antibiotics, or individuals with severe liver or kidney disease cannot join. Patients with mental health conditions that make it difficult to understand study instructions are also excluded.
Focus of the trial: The study aims to determine whether customized antibiotic treatment duration, based on when patients achieve clinical stability, is as effective as standard longer treatment courses. Researchers will monitor patients for 30 days, checking for sustained recovery, the need for additional antibiotics, and overall health outcomes. The trial also assesses the impact on quality of life and any side effects experienced during treatment.
Investigational drugs: The trial tests an experimental strategy involving several antibiotics including amoxicillin, amoxicillin combined with a beta-lactamase inhibitor, pristinamycin, levofloxacin, ceftriaxone, and cefotaxime. These medications can be given orally or through injections, depending on the patient’s condition. The key innovation is not the drugs themselves, but the approach to stopping treatment when specific stability criteria are met after at least 48 hours of therapy.
Study on Inhaled Levofloxacin for Treating Community-Acquired Pneumonia in Patients Without Systemic Antibiotics
This trial is being conducted in Denmark and investigates whether inhaling an antibiotic directly into the lungs is as effective as receiving antibiotics intravenously through the bloodstream. The study compares these two different treatment approaches for community-acquired pneumonia.
Who can participate: The trial is open to adults aged 18 years or older who have been admitted to the hospital within the last 24 hours with a new chest problem visible on X-ray that looks like pneumonia. Participants must have symptoms such as fever, cough, producing mucus, difficulty breathing, or chest pain. The attending physician must determine that the patient needs treatment with intravenous piperacillin/tazobactam, and patients must have either a C-reactive protein level greater than 50 or a body temperature higher than 38.0°C. C-reactive protein is a substance in the blood that increases when there is inflammation or infection.
Who cannot participate: Patients currently taking other antibiotics not part of the study cannot join. Those with a history of allergic reactions to the study medications, severe liver or kidney problems, or who are pregnant or breastfeeding are excluded. Individuals with other serious health conditions that might interfere with the study, those who participated in another clinical trial recently, or those unable to follow study procedures are also not eligible.
Focus of the trial: The study’s main goal is to determine if inhaled levofloxacin treatment is as effective as intravenous piperacillin/tazobactam in helping patients recover from pneumonia. Researchers will monitor how many days patients are alive and out of the hospital within 14 days after starting treatment. The trial also examines side effects, changes in gut bacteria diversity, overall health outcomes at 30 days, and patient-reported symptoms such as difficulty breathing, cough, and fatigue.
Investigational drugs: The trial tests levofloxacin, given through inhalation at a dose of 240 mg twice daily for 4 to 5 days. This is compared with piperacillin/tazobactam, a combination of two antibiotics given intravenously. Levofloxacin works by preventing bacteria from replicating their DNA, while piperacillin interferes with bacterial cell wall formation and tazobactam prevents bacterial resistance to the antibiotic.
Summary
The two ongoing clinical trials for community-acquired pneumonia represent innovative approaches to antibiotic treatment. One trial in France focuses on personalizing treatment duration based on clinical stability markers, potentially reducing unnecessary antibiotic use while maintaining treatment effectiveness. The other trial in Denmark explores whether inhaling antibiotics directly into the lungs could be as effective as traditional intravenous administration.
Both studies reflect a growing interest in optimizing antibiotic therapy to improve patient outcomes while addressing concerns about antibiotic resistance and treatment burden. The trials are geographically distributed across Europe, with each country contributing unique research perspectives. The French study tests multiple antibiotic options including amoxicillin, cefotaxime, and levofloxacin, while the Danish study specifically compares inhaled levofloxacin with intravenous piperacillin/tazobactam.
These trials aim to provide evidence-based guidance for treating community-acquired pneumonia more effectively, potentially reducing hospital stays and improving patients’ quality of life during recovery.
